Ripped 2.0 Injectable (RAD-140 + S4 Andarine + S-23 + YK-11)

Description

Ripped 2.0 Injectable (RAD-140 + S4 Andarine + S-23 + YK-11)

• Ripped 2.0 consists of RAD-140, S4 Andarine, S-23, and YK-11.
• Ripped 2.0 is offered as 30mg RAD 140, 30mg S4, 15mg S-23, and 5mg YK-11, totaling 80mg per ml for 10 ml or 800mg in total.

RAD-140

The first compound in ripped 2.0 injectable is Testolone. Testolone, often referred to as RAD 140, is currently under thorough investigation as a research compound, with a specific focus on its potential to augment muscle hypertrophy. Ongoing studies delve into the preclinical characterization of selective androgen receptor modulators, emphasizing their anabolic activity in male cynomolgus monkeys. A key metric under scrutiny to assess anabolic activity is gross body weight, recognized as a sensitive indicator of anabolic androgen action in young nonhuman primates. The outcomes of a study involving a 28-day dosing regimen with RAD140 revealed statistically significant changes in animal body weight, signaling substantial promise in the potential for muscular gains attributed to Testolone. These findings contribute to the evolving understanding of RAD 140’s impact on muscle development, paving the way for further exploration and potential applications in the field of muscle enhancement research.

S4 Andarine

Another compound part of ripped 2.0 injectable is S4. S4, also known as Andarine, is a type of selective androgen receptor modulator (SARM). It is a synthetic compound that selectively binds to androgen receptors in the body, influencing the expression of genes associated with muscle and bone growth. SARMs like S4 are designed to provide anabolic effects in specific tissues, such as muscles and bones, while minimizing the androgenic effects typically associated with traditional anabolic steroids.

In a notable scientific study from 2005, the impact of Andarine S-4 on skeletal muscles, bones, and pituitary glands was investigated in castrated male rats. Employing a treatment protocol involving two different doses (3 and 10mg/kg of S4- Andarine for 8 weeks), the study commenced 12 weeks post-castration. Encouragingly, Andarine, particularly at doses of 3 and 10 mg/kg, demonstrated a capacity to restore both soleus muscle mass and strength, as well as levator ani muscle mass, akin to levels observed before castration or in intact animals.

These findings position S4 as a compelling investigational Selective Androgen Receptor Modulator (SARM), holding promise for potential applications in conditions associated with muscle wasting, osteoporosis, and benign prostatic hyperplasia (BPH). Notably, S4 showcases the ability to mimic several of the beneficial pharmacologic effects classically associated with testosterone. As research in this realm progresses, S4’s therapeutic potential and safety profile warrant further exploration for potential clinical use.

S-23

S-23 is the next compound in the ripped 2.0 injectable. S23 is a type of selective androgen receptor modulator (SARM), a class of compounds designed to selectively target and interact with androgen receptors in the body. Selective androgen receptor modulators are being researched for their potential therapeutic applications, particularly in areas such as muscle wasting, osteoporosis, and hormonal disorders.

Based on existing studies, the S23 SARM has demonstrated the induction of temporary infertility in all rats exposed to it, with the effects being dose-dependent. Notably, fertility was restored in the rats post-treatment, suggesting the potential of S23 as an oral male contraceptive. The research underscores S23’s impact on reproductive hormones, specifically subduing serum concentrations of luteinizing hormone and follicle-stimulating hormone, resulting in biphasic effects on spermatogenesis. While the findings provide intriguing insights into S23’s contraceptive potential, further research and clinical trials are imperative to establish its efficacy and safety as an oral contraceptive.

Beyond its contraceptive effects, the study revealed additional positive outcomes. Notably, S23 exhibited a stronger affinity to androgen receptors compared to popular compounds like Andarine, presenting an advantageous characteristic. Its favorable anabolic-androgenic ratio positions it as a compound capable of generating positive effects without severe complications. Among these effects, S23 showcased the ability to increase bone mineral density and promote lean muscle mass.

Consequently, while S23 holds promise as a potential male birth control pill, its versatility extends to other research purposes. Particularly, its exploration among subjects with chronic conditions leading to muscle wasting could unveil additional therapeutic applications. This highlights the multifaceted nature of S23, warranting continued investigation for its diverse physiological effects and potential clinical applications.

YK-11

Fourth compound in the ripped 2.0 injection is YK-11. YK11 represents a recent addition to synthetic steroids, crafted from the well-known 5-α-dihydrotestosterone (DHT), a naturally occurring hormone within the human body. DHT, recognized as a potent form of testosterone, selectively targets androgen receptors in key areas such as sex organs, the prostate, liver, and hair follicles. Despite its classification as a synthetic steroid, YK11 is frequently misconstrued as a non-steroidal selective androgen receptor modulator (SARM). This compound has sparked significant interest among bodybuilders who perceive its potential to expedite muscle growth with minimal side effects.

Contrary to its SARM-like reputation, YK11 shares more similarities with traditional steroids. The compound has garnered attention due to its perceived efficacy in promoting muscle development, and this belief is supported by preliminary cell studies conducted on mice. These studies suggest that YK11 has the potential to augment muscle mass and contribute to improved bone health, further fueling the intrigue surrounding its application in bodybuilding circles.